Kishwar Ali, MD
Psychiatry · Aurora, ILNPI 1740385855
Payments from drug & device makers
Across 43 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$4K
- AbbVie$472
- Adlon Therapeutics L.p.$39
- Otsuka America Pharmaceutical, Inc.$32
- Johnson & Johnson$27
- Neurocrine Biosciences, Inc.$16
- plus $54 from 4 others
What the payments were for
- Food & beverage$1,13424%
- Other$3,50076%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 7 | $3,993 |
| AbbVie(2 entities) | 25 | $472 |
| Adlon Therapeutics L.p. | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Indivior Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,634 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $2,436 |
| Quetiapine Fumarate | 31 | $1,792 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,078 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $685 |
| Prazosin Hcl | 14 | $602 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $522 |
| Sertraline Hcl | 46 | $395 |
| Trazodone Hcl | 42 | $331 |
| Duloxetine Hcl | 16 | $327 |
| Escitalopram Oxalate | 17 | $270 |
| Hydroxyzine Hcl | 23 | $246 |
| Divalproex Sodium | 11 | $244 |
| Gabapentin | 14 | $243 |
| Lorazepam | 36 | $217 |
| Benztropine Mesylate | 17 | $197 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Aurora
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.